In this Perspective, we provide an overview of available mouse models of acute and chronic GvHD, discuss their uses and limitations, and provide guidance on selecting an appropriate model.

Charles River offers allogeneic and xenogeneic preclinical Graft vs Host Disease (GVHD) mouse models. The GvHD model can be used to model the disease side effect of hematopoietic stem cell transplantation, or can be used as a screening model for drugs that are immunostimulating.

Sep 26, 2019 · Aiming for a higher translational value, we constructed an MHC major mismatched [C57BL/6 (H-2 Kb) to BALB/c (H-2Kd)] aGVHD mouse model based on busulfan/cyclophosphomide (BU–CY) conditioning...

Jan 1, 2022 · Here, we describe basic murine protocols by which to accurately and reproducibly model both aGVHD and cGVHD. The first step is to develop mouse models that attempt to recapitulate either aGVHD or cGVHD.

Feb 28, 2009 · Acute GVHD is responsible for 15% to 40% of mortality and is the major cause of morbidity after allogeneic HCT, while chronic GVHD occurs in up to 50% of patients who survive three months after HCT. Mouse models have provided the majority of insights into the biology of this complex disease process.

In this Perspective, we provide an overview of currently available mouse models of acute and chronic GvHD, highlighting their benefits and limitations, and discuss research and clinical opportunities for the future.

Mar 19, 2025 · The injection of C57BL/6J mouse cells into Balb/c mice triggers a GVHD reaction. Likewise, the injection of Balb/c mouse cells into C57BL/6J mice triggers a GVHD reaction. The allogeneic model using Balb/c mice as recipients progresses rapidly, with severe symptoms appearing quickly and mortality occurring within a maximum of 15 days.

Mar 19, 2025 · Humanized mouse model of graft-versus-host disease (GVHD). Nonirradiated NSG mice receive an intraperitoneal (i.p.) injection of 10 × 10 6 human peripheral blood mononuclear cells (PBMCs) on day 0. The mice are monitored for clinical signs of disease at least three times a week from day 0 to humane (ethical) or experimental endpoint.

A notable limitation of mouse models investigating novel GVHD therapies, however, is that the majority do not use steroid-refractory models, a factor that has been cited as the potential cause of novel treatment failure in the clinical setting [].Developing mouse models of SR-GVHD has become a focus for GVHD research, with several recently published models [52,53,54], which may provide a ...

In this chapter, we describe allo-HCT mouse models and protocols using these mouse models by which to study acute and chronic GVHD with the goal of improving prevention and therapy. Keywords: Acute GVHD; Chronic GVHD; JAK/STAT; Modeling; Spleen; T-cells.